Kansas lawmakers gave tax-free public financing to a powerful private interest.
The Proposed Musk Efficiency Commission Could Save Trillions
Trump saying that trillions of dollars can be saved from a government efficiency commission headed by Musk isn’t an exaggeration.
Price Controls Are Always a Bad Idea
Prices controls have always disrupted the marketplace and created shortages or excesses.
The Future of the Universal Service Fund
To save taxpayer dollars, Congress should look at revamping the USF program instead of trying to expanding its contribution base.
USPTO-FDA Study Debunks Critics and Demonstrates the Importance of Protecting IP
USPTO-FDA study reinforces the need to protect pharmaceutical intellectual property rights for the future of new drug development.
The IRA Has Undermined Medicare Part D
The Inflation Reduction Act creates instability in the Medicare Part D Program.
Not-So-Happy Birthday to the Inflation Reduction Act
The Inflation Reduction Act will ultimately raise drug costs and reduce future cures.
The FTC Wrongly Blames PBMs for High Drug Prices
Putting the customer at the core of your product development ensures relevance and resonance.
New Study Shows PBMs Lower Drug Prices
A new report challenges assertions made during the committee’s recent hearing on the role of pharmacy benefit managers.
USPS Plan Cannot Be Delivered As PMG DeJoy Obstinately Claims
Despite growing evidence of problems, PMG DeJoy doubles down on his Delivering for America plan to supposedly save USPS.